Trials / Recruiting
RecruitingNCT06603246
A Study to Test the Safety and Effects of Inhaled GDC-6988 in Participants With Muco-obstructive Disease
A Phase Ic, Open-label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of Inhaled GDC-6988 in Patients With Muco-obstructive Disease
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 128 (estimated)
- Sponsor
- Genentech, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study evaluates the safety, tolerability, and activity of inhaled GDC-6988 in participants with muco-obstructive disease.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GDC-6988 | GDC-6988 will be administered using a dry powder inhalation (DPI) device. |
Timeline
- Start date
- 2024-11-18
- Primary completion
- 2027-11-15
- Completion
- 2027-11-15
- First posted
- 2024-09-19
- Last updated
- 2026-04-13
Locations
7 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06603246. Inclusion in this directory is not an endorsement.